{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:45:36Z","timestamp":1792629936917,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874104"],"award-info":[{"award-number":["81874104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12021113"],"award-info":[{"award-number":["SHDC12021113"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>FDX1 participates in cuproptosis, a copper-dependent cell death mode, which might influence tumor progressions like ferroptosis and pyroptosis. However, the role of FDX1 in tumors remains to be explored. This study investigated FDX1 expression features, and correlations to prognosis, tumor stages, immune microenvironment, and cuproptosis from a pan-cancer perspective based on integrated bioinformatics. FDX1 mRNA and clinical data were obtained from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Broad Institute Cancer Cell Line Encyclopedia (CCLE) databases. Differential expression of FDX1 in tumor stages was performed on GEPIA2.0. Cox proportional hazard regression and survival curve were used to analyze the prognostic value of FDX1. The relationships between FDX1 expression and immune infiltration, immune cells, immune checkpoints, tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), and DNA methyltransferase (DNMT) were explored. GSEA was utilized to find the biological function of FDX1 in LGG. Results showed that FDX1 was abnormally expressed in multiple tumor types and demonstrated variability in various tumor stages. Survival analysis revealed FDX1 predicted poor prognosis in glioma (GBMLGG), brain lower-grade glioma (LGG), and good prognosis in the pan-kidney cohort (KIPAN), and kidney renal clear cell carcinoma (KIRC). Immune correlation analysis suggested FDX1 showed positive correlations to StromalScore, ImmuneScore, ESTIMATEScore in LGG and negative correlation in KIRC. Additionally, positive correlations were observed between FDX1 and immune cells infiltration, immune checkpoints, tumor stemness, homologous recombination deficiency (HRD), and TMB in LGG in the pan-cancer analysis. Validation with CGGA suggested prognostic value and immune correlation of FDX1 in LGG. Specifically, high expression of FDX1 was accompanied by high expression of immune checkpoints such as CD276 (B7-H3), CD274 (PD-L1), PDCD1LG2 (PD-L2), CTLA4, and HAVCR2. These findings illustrated that FDX1 might be considered a potential poor prognosis biomarker and immunotherapy predictor in LGG.<\/jats:p>","DOI":"10.3389\/fmolb.2023.963639","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:29:59Z","timestamp":1675751399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas"],"prefix":"10.3389","volume":"10","author":[{"given":"Wei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.Cd-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.can-15-2125","article-title":"Combining epigenetic and immunotherapy to combat cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","article-title":"Targeting signalling pathways and the immune microenvironment of cancer stem cells \u2014 A clinical update","volume":"17","author":"Clara","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1002\/ctm2.492","article-title":"Pyroptosis, metabolism, and tumor immune microenvironment","volume":"11","author":"Du","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, idh, and tert promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","article-title":"The role of necroptosis in cancer biology and therapy","volume":"18","author":"Gong","year":"2019","journal-title":"Mol. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.can-17-0307","article-title":"Timer: A web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.nicl.2018.10.014","article-title":"A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas","volume":"20","author":"Liu","year":"2018","journal-title":"NeuroImage-Clin"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"Esmo recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with Pd-1\/Pd-L1 expression and tumour mutational burden: A systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Peter","year":"2022","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined parp inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for rna-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.1073\/pnas.1004250107","article-title":"Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe\/S cluster biosynthesis","volume":"107","author":"Sheftel","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","article-title":"Ferroptosis, necroptosis, and pyroptosis in anticancer immunity","volume":"13","author":"Tang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"Gepia2: An enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"15","author":"Tsvetkov","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","article-title":"Iobr: Multi-Omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: A novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"749134","DOI":"10.3389\/fphar.2021.749134","article-title":"Fdx1 can impact the prognosis and mediate the metabolism of lung adenocarcinoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.963639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T06:30:02Z","timestamp":1675751402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.963639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":25,"alternative-id":["10.3389\/fmolb.2023.963639"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2023.963639","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"963639"}}